Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same
historically intransigent problem that has existed since the initial description of the disease in …

The transcription factor NRF2 (nuclear factor erythroid 2‐related factor 2) triggers the first
line of homeostatic responses against a plethora of environmental or endogenous …

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous
system (CNS) where immunopathology is thought to be mediated by myelin-reactive CD4+ T …

There is growing recognition that B cell contributions to normal immune responses extend
well beyond their potential to become antibody-producing cells, including roles at the innate …

The disruption of blood–brain barrier (BBB) for multiple sclerosis (MS) pathogenesis has a
double effect: early on during the onset of the immune attack and later for the CNS self …

Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the
progressive loss of axonal myelin in several areas of the central nervous system (CNS) that …

Dimethyl fumarate (DMF) is an effective treatment option for relapsing–remitting multiple
sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A …

Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …

Pro‐inflammatory signals induce metabolic reprogramming in innate and adaptive immune
cells of both myeloid and lymphoid lineage, characterized by a shift to aerobic glycolysis …

Abstract The coronavirus disease 2019 (COVID-19) pandemic is concerning for patients with
neuroimmunological diseases who are receiving immunotherapy. Uncertainty remains …